PROLOR Biotech Receives Notice of Allowance for New U.S. Patent Covering Methods for Decreasing Body Fat with hGH-CTP

   PROLOR Biotech Receives Notice of Allowance for New U.S. Patent Covering
                 Methods for Decreasing Body Fat with hGH-CTP

PR Newswire

NES-ZIONA, Israel, March 5, 2013

NES-ZIONA, Israel, March 5, 2013 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE
MKT: PBTH) today announced that it has received a notice of allowance from the
U.S. Patent and Trademark Office (USPTO) for a new patent application covering
the company's long-acting CTP-enhanced human growth hormone (hGH-CTP).Upon
issuance, the new patent will provide PROLOR with additional intellectual
property protection that covers methods for decreasing body fat in humans
through the use of hGH-CTP therapy.

"Treatment with human growth hormone may help decrease the excessive body fat
that can characterize growth hormone deficiency in adults," said Shai Novik,
president of PROLOR."We believe that this new U.S. patent allowance further
reinforces our already substantial patent portfolio for our lead compound,
hGH-CTP, as we prepare to commence Phase III trials expected to begin later
this year."

This new patent allowance is the fifth for hGH-CTP that has been awarded by
the USPTO since 2009. The patent is expected to issue in the next few months.

Previously reported data from the company's Phase II trial of hGH-CTP in
growth hormone deficient adults showed that hGH-CTP has the potential to
reduce the required dosing frequency of human growth hormone from the current
standard of one injection per day to a single weekly injection.In that trial,
hGH-CTP demonstrated a good safety and tolerability profile. A Phase II trial
in growth hormone deficient children is currently ongoing.

ABOUTPROLOR
PROLOR Biotech, Inc. is a clinical stage biopharmaceutical company applying
unique technologies, including patented CTP technology, primarily to develop
longer-acting proprietary versions of already approved therapeutic proteins
that currently generate billions of dollars in annual global sales.The CTP
technology is applicable to virtually all proteins.PROLOR is currently
developing a long-acting version of human growth hormone, which successfully
completed a Phase II clinical trial.It also is developing long-acting
versions of Factor VIIa and Factor IX for hemophilia and a GLP-1/Glucagon dual
receptor agonist peptide for diabetes and obesity, all of which are in
preclinical development. For more information, visit
http://www.prolor-biotech.com.

Safe Harbor Statement: This press release contains forward-looking
statements, which may be identified by words such as "expects," "plans,"
"projects," "will," "may," "anticipates," "believes," "should," "would",
"intends," "estimates," "suggests," "has the potential to" and other words of
similar meaning, including statements regarding the results of current
clinical studies and preclinical experiments and the effectiveness of PROLOR's
long-acting protein programs, which are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995. Investors
are cautioned that forward-looking statements involve risks and uncertainties
that may affect PROLOR's business and prospects, including the risks that
PROLOR may not succeed in generating any revenues or developing any commercial
products, including any long-acting versions of human growth hormone,
erythropoietin, interferon beta, GLP-1 and other products; that the
long-acting products in development may fail, may not achieve the expected
results or effectiveness and/or may not generate data that would support the
approval or marketing of these products for the indications being studied or
for other indications; that ongoing studies may not continue to show
substantial or any activity; that the actual dollar amount of any grants from
Israel's Office of the Chief Scientist is uncertain and is subject to policy
changes of the Israeli government, and that such grants may be insufficient to
assist with product development; and other risks and uncertainties that may
cause results to differ materially from those set forth in the forward-looking
statements. The results of clinical trials in humans may produce results that
differ significantly from the results of clinical and other trials in animals.
The results of early-stage trials may differ significantly from the results of
more developed, later-stage trials. The development of any products using the
CTP platform technology could also be affected by a number of other factors,
including unexpected safety, efficacy or manufacturing issues, additional time
requirements for data analyses and decision making, the impact of
pharmaceutical industry regulation, the impact of competitive products and
pricing and the impact of patents and other proprietary rights held by
competitors and other third parties. In addition to the risk factors
described above, investors should consider the economic, competitive,
governmental, technological and other factors discussed in PROLOR's filings
with the Securities and Exchange Commission. The forward-looking statements
contained in this press release speak only as of the date the statements were
made, and we do not undertake any obligation to update forward-looking
statements, except as required under applicable law.

PROLOR CONTACT:         MEDIA CONTACT:
Shai Novik, President   Barbara
                        Lindheim
PROLOR Biotech, Inc.    BLL Partners, LLC
Tel: +1 866 644-7811    +1 212 584-2276
Email:                  blindheim@bllbiopartners.com
shai@prolor-biotech.com

SOURCE PROLOR Biotech, Inc.

Website: http://www.prolor-biotech.com
 
Press spacebar to pause and continue. Press esc to stop.